Healthcare Industry News: dialysis
News Release - December 9, 2011
Bluegrass Vascular Technologies Begins First Clinical Study of the Surfacer(TM) Inside-Out Access Catheter SystemLEXINGTON, Ky.--(Healthcare Sales & Marketing Network)-- Bluegrass Vascular Technologies, a medical technology company focused on life-saving devices and methods for vascular access procedures, has announced patient enrollment in the first clinical study of its Surfacer™ Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel “inside-out” approach to gain venous access. The prospective single-center feasibility study will evaluate the safety and effectiveness of the Surfacer in up to 10 patients with upper extremity venous occlusion (or blockage in the vein). Conducted by Principal Investigator Dr. Adrian Ebner at the Sanitorio Italiano in Asunción, Paraguay, the study commenced with the successful treatment of six patients in early December.
“Our early experience with the Surfacer has shown it to hold significant promise for regaining access in patients whose veins have become totally compromised with occlusion, thereby limiting their ability to receive critical vascular access therapies such as dialysis and intravenous chemotherapy,” said Dr. Ebner. “The Surfacer’s unique inside-out approach is minimally invasive and simple to perform, and it has demonstrated the ability to reestablish access in the first series of study patients. Based on these early clinical results, I believe the Surfacer has the potential to ultimately eliminate the undue risk and associated cost of more invasive procedures that, until now, have been the only alternative for regaining access.”
The Surfacer was developed to provide a new option for patients with upper extremity venous occlusions that make veins impenetrable by a guide wire or standard access techniques. This condition is seen in patients treated frequently with central venous catheters for the delivery of dialysis or nutrition, to implant pacemakers, or to administer intravenous chemotherapy. Bluegrass Vascular estimates that more than three million patients require central venous access for medical treatment in the United States alone.
When an occlusion occurs in the patient’s vein, the vein becomes compromised and unusable for further access, requiring the physician to seek access through another vein. If all four central veins become compromised, a high-risk, invasive surgical procedure through the chest or torso remains the only option for reestablishing access.
The Surfacer was designed to offer a safer and simpler long-term access alternative. Using the system, physicians insert a guide wire through the femoral vein in the groin area and, using fluoroscopy, navigate it up through the torso with an exit point in the jugular vein in the neck or the subclavian vein under the collarbone. The procedure is performed while the patient is under conscious sedation as with other vascular access procedures.
“The commencement of our first clinical study of the Surfacer is a significant achievement that moves us closer to our goal of offering physicians and their patients game-changing technologies that save veins and save lives,” said James Clifton, president of Bluegrass Vascular Technologies. “We are thrilled to be underway with this important research and look forward to announcing the study findings in 2012.”
About Bluegrass Vascular Technologies
Founded in 2011 and based in Lexington, Ky., Bluegrass Vascular Technologies is a medical technology company dedicated to developing and commercializing life-saving devices and methods that address shortcomings in vascular access procedures. The company’s initial product offering is the Surfacer™ Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel “inside-out” approach to gaining venous access. For more information, please visit www.bluegrassvascular.com.
Source: Bluegrass Vascular Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.